CTi Biopharma Corp Alpha and Beta Analysis

CTICDelisted Stock  USD 9.09  0.00  0.00%   
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as CTi Biopharma Corp. It also helps investors analyze the systematic and unsystematic risks associated with investing in CTi Biopharma over a specified time horizon. Remember, high CTi Biopharma's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to CTi Biopharma's market risk premium analysis include:
Beta
0.93
Alpha
1.41
Risk
0.0
Sharpe Ratio
0.0
Expected Return
0.0
Please note that although CTi Biopharma alpha is a measure of relative return and represented here as a single number, it indicates the percentage above or below your selected benchmark (i.e., Dow Jones Industrial index.) So in this particular case, CTi Biopharma did 1.41  better than the index. Remember, a high alpha is always good. Beta, on the other hand, measures the volatility (or risk) of an investment. It is an indication of CTi Biopharma Corp stock's relative risk over its benchmark. CTi Biopharma Corp has a beta of 0.93  . CTi Biopharma returns are very sensitive to returns on the market. As the market goes up or down, CTi Biopharma is expected to follow. .
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
  
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

CTi Biopharma Market Premiums

Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. CTi Biopharma market risk premium is the additional return an investor will receive from holding CTi Biopharma long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in CTi Biopharma. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate CTi Biopharma's performance over market.
α1.41   β0.93

CTi Biopharma Fundamentals Vs Peers

Comparing CTi Biopharma's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze CTi Biopharma's direct or indirect competition across all of the common fundamentals between CTi Biopharma and the related equities. This way, we can detect undervalued stocks with similar characteristics as CTi Biopharma or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of CTi Biopharma's fundamental indicators could also be used in its relative valuation, which is a method of valuing CTi Biopharma by comparing valuation metrics with those of similar companies.
    
 Better Than Average     
    
 Worse Than Average Compare CTi Biopharma to competition
FundamentalsCTi BiopharmaPeer Average
Return On Equity-10.19-0.31
Return On Asset-0.29-0.14
Profit Margin(0.91) %(1.27) %
Operating Margin(0.74) %(5.51) %
Current Valuation1.26 B16.62 B
Shares Outstanding131.88 M571.82 M
Shares Owned By Insiders5.49 %10.09 %

CTi Biopharma Opportunities

CTi Biopharma Return and Market Media

The Stock received substential amount of media coverage during this period.
 Price Growth (%)  
       Timeline  
1
Is CTI BioPharma Corp a Bad Choice in Biotechnology Thursday - InvestorsObserver
03/30/2023
2
CTI BioPharma Shares Soar Premarket on Takeover by Swedish Orphan CTIC
05/10/2023
3
CTi Biopharma earnings beat, revenue topped estimates
05/12/2023
4
CTI BioPharma Q1 Earnings Snapshot
05/16/2023
5
SHAREHOLDER INVESTIGATION Halper Sadeh LLC Investigates FOCS, HMPT, CTIC
05/18/2023
6
Top 5 Health Care Stocks That Should Keep You Up At Night By ... - Investing.com UK
05/23/2023
7
Gyon Technologies Capital Management LP Raises Position in CTI BioPharma Corp.
06/09/2023
8
Disposition pursuant to a tender of shares in a change of control transaction by Reed Tuckson of CTi Biopharma
06/26/2023

About CTi Biopharma Beta and Alpha

For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including CTi or other delisted stocks. Alpha measures the amount that position in CTi Biopharma Corp has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.

CTi Biopharma Upcoming Company Events

As portrayed in its financial statements, the presentation of CTi Biopharma's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, CTi Biopharma's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of CTi Biopharma's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of CTi Biopharma. Please utilize our Beneish M Score to check the likelihood of CTi Biopharma's management manipulating its earnings.
14th of August 2023
Upcoming Quarterly Report
View
6th of November 2023
Next Financial Report
View
30th of June 2023
Next Fiscal Quarter End
View
4th of March 2024
Next Fiscal Year End
View
31st of March 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Build Portfolio with CTi Biopharma

Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.

Build Diversified Portfolios

Align your risk with return expectations

By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.

Other Consideration for investing in CTi Stock

If you are still planning to invest in CTi Biopharma Corp check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the CTi Biopharma's history and understand the potential risks before investing.
Bonds Directory
Find actively traded corporate debentures issued by US companies
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA